Pfizer stock: Robust earnings and clinical progress boost a 3.02% rise

Traders Union
All News
Financial News
Pfizer gains 3.02% to $27.29 today

Highlights

Pfizer beat Q4 revenue and adjusted EPS expectations, guiding a full-year 2024 adjusted gross margin at 74% and highlighting a Q4 margin impact from COVID-19 product mix.
The company reduced debt by $7.8 billion in 2024, reaffirmed its leverage reduction plan, and declared a $0.43 per share dividend for March 6th.
Pfizer trades at $27.29 above its MA-20, MA-50, and MA-200, with key support at $26.01 and resistance near $28, as momentum remains bullish but overbought conditions signal possible short-term pause.

Earnings beat, margin guidance, and debt cuts sustain dividend focus

Pfizer reported stronger-than-expected revenue and adjusted EPS for the fourth quarter, with full-year 2024 adjusted gross margin guided at 74% and Q4 margin at 68% due to COVID-19 product mix but supported by cost management actions. The company reduced its debt by $7.8 billion in 2024, aligning with its leverage reduction plan, and reaffirmed its commitment to grow the dividend, scheduling a $0.43 per share payout for March 6th. Pfizer's clinical portfolio made progress with positive Phase 2b data for its GLP-1 obesity drug and continued pipeline investments, though attention remains on portfolio growth following the Seagen acquisition and on dividend sustainability as earnings coverage remains tight.

Overbought signals emerge as buyers fuel momentum toward resistance

On the daily chart, the nearest dynamic support for PFE is the Ichimoku Kijun at $26.01, while key resistance sits at the MA-50 and the psychologically significant $28 level. Momentum is positive with strong readings on the MACD and ADX, indicating underlying bullish strength, but oscillators show caution: the RSI is neutral at 56.37, and both the Stochastic RSI and Commodity Channel Index signal overbought conditions. Bull/Bear Power remains strongly positive, confirming buyers’ control in the intraday session, with the Awesome Oscillator also supporting the upward trend. Trading near the session high of $27.30 reflects robust intraday momentum and moderate volatility, though the overbought readings highlight potential for a near-term pause or pullback.

Bullish trend consolidates as breakout and correction risks diverge

For the coming five trading days, PFE is expected to fluctuate within a typical volatility band of $27.24 to $27.85 as the bullish trend consolidates. The probability of further increases remains high, and a breakout above resistance near $28 could trigger a more extended move higher as buyers remain in control. However, a break below support at the Ichimoku Kijun around $26.01 would open the door to correction, especially if overbought conditions trigger profit-taking.

Viktoras Karapetjanc, Traders Union expert, sees Pfizer maintaining bullish momentum both fundamentally and technically. Solid earnings, robust margins, and active debt reduction underpin investor confidence. The positive reaction to pipeline progress and shareholder returns confirms strong sentiment in the stock. Near-term, he notes that resistance at $28 and overbought conditions could briefly pause the rally, but buyers still have the upper hand. "With fundamentals and sentiment aligning, any pullback is likely to be short-lived — I expect Pfizer to build on its current gains if support at $26.01 holds."

Previously it was reported that Pfizer shares are trading strongly above key short-, medium-, and long-term moving averages, with momentum indicators such as MACD and ADX supporting a continued bullish trend. However, overbought signals from oscillators and elevated CCI suggest the stock may face short-term exhaustion despite maintaining support above $26.01 and resistance near current levels.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.